Join The Conversation!
https://bit.ly/SurfingNASHPodcast

Mazen Noureddin joins the Surfers to explore the issues and needs that will shape treatment guidelines in a world after NASH drugs come to market.

In Season 2 Episode 16, a discussion of cost-effectiveness led to the question, "How will treatment pathways and rules evolve as new NASH drugs come to market." Mazen Noureddin, who raised this issue with Stephen Harrison in the earlier episode, returns to explore the answer ten episodes later.

The discussion considers what the phrase "backbone therapy" will mean in the future of NASH therapy and which agent(s) might attain that status. It considers how treatment models might vary for patients with cirrhosis vs. those with NASH, and for compensated cirrhosis vs. decompensated cirrhosis. It explores the role that AI-driven algorithms powered through electronic records will play in helping primary care physicians, general gastroenterologists and general hepatologists (if there is such a thing) treat patient who might have not only NASH but a range of accompanying metabolic conditions.

This discussion covers a lot of ground in a very short time. It stimulates and challenges. Enjoy it!

S2-E26 - What Will Treatment Pathways Look Like For NASH Patients?

Drug developers, investors, researchers, and corporate executives wrestle weekly to understand what is happening in commercial development of NASH medications. Hepatology researcher and Key Opinion Leader Stephen Harrison, M.D., C-suite veteran Peter Traber, M.D., and Forecasting and pricing guru Roger Green, M.B.A. discuss the issues affecting the evolving NASH market from their own unique perspectives on the Surfing the NASH Tsunami podcast.

S2-E26 - What Will Treatment Pathways Look Like For NASH Patients?

SurfingMASH